{'fraction_non_alphanumeric': 0.029310344827586206, 'fraction_numerical': 0.02327586206896552, 'mean_word_length': 5.015544041450777, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Binding in vivo of enhancing antibodies to skin allografts and specific allogeneic tissues.


 Binding of antibodies with enhancing quality to target skin grafts and to allogeneic tissue was studied in vivo. The alloantibodies were 125I-labeled enriched IgG fraction (125I-EIgG) of Lewis (Le) antisera and were paired with 131I-labeled IgG (131I-ClgG) of control Le sera. 125I-EIgG was specifically bound to target skin grafts within 2 days after grafting and was blocked from localizing in skin grafts by unlabeled enhancing antisera given at the time of grafting (“afferent” blockade). Alloantigenic sites were blocked for several days, after which time skin grafts bound 125I-EigG for up to 40 days. Blocking in vitro of alloantigenic sites was demonstrated and quantitated. Enhancing antibodies generated by long-term enhanced skin grafts on Le hosts (auto-enhancement) were not detected in the circulation. 125I-EIgG disappeared from the circulation of allogeneic rats and was specifically localized in spleen, lung and liver, but not in kidney. 125I-EIgG persisted in the circulation of syngeneic hosts and was not specifically localized in their organs.